SBIR/STTR Research Award

PET and SPECT Ligands for Imaging Apoptosis

Award identifier 8c18b0a20a8391a2d1a3ed1722b16d7a8e2c40f7d4ee0e10ec3feee5f393fa07Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$490,126

Program and phase

STTR · Phase I

Award year

2008

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
IMMUNOCHEMISTRY TECHNOLOGIES, LLC
Proposal award date
Not reported
Contract end date
Not reported
UEI
NULBVXPJJUU6
Solicitation number
PHS2007-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): PET and SPECT Ligands for Imaging Neuronal Apoptosis Abstract: Activation of the intracellular caspase cascade is a well understood signaling mechanism that results in apoptosis. The identification of apoptotic events i n vivo has important applications for detecting cell death induced by disease, injury, therapeutics, or normal tissue development and differentiation. Further advances in these lines of investigation increasingly call for in vivo methods and probes for det ection and imaging of intracellular signaling events. This 2 year Phase I STTR application proposes to conjugate a radiolabel to the pan caspase inhibitor VAD-FMK. This probe will provide a new tool for the non-invasive imaging of caspase-mediated apoptoti c events in vivo using PET or SPECT imaging. In the first year of the proposal, eight VAD- FMK analogs will be synthesized to devise the optimal reagent probe. The newly synthesized probes will be evaluated for their ability to detect caspase activity in v itro. By the end of the first year, we will select the four best candidates to radiolabel for the next stage of assessing their pharmacodynamics/pharmacokinetics in normal mice. Finally, we will utilize a mouse model of the neurodegenerative disease multip le sclerosis to evaluate the best two candidate probes for their suitability as a non-invasive in vivo apoptosis detection reagent. Accordingly, the Specific Aims of this proposal are: I. Synthesis of non-radioactive VAD-FMK compounds and validation of the ir caspase-binding activity, II. Radiolabeling of the candidate probes and measurements of in vivo uptake and biodistribution in normal mice, and III. Evaluation of RC-VAD-FMKs as in vivo detectors of apoptosis in EAE. It is expected that completion of the se three specific aims will lead to a Phase II STTR that will proceed into pre-clinical development of the prototypical radiotracer for in vivo detection of neuronal apoptosis. PUBLIC HEALTH RELEVANCE: Cells in the nervous system may die as a result of dis ease, radiation damage, chemotherapy, or normal aging. This project will produce a probe that can detect cell death inside a living organism. This new tool will help researchers understand how cell death occurs and may suggest new treatments or preventive measures for protecting against neuronal cell death.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

3 SBIR/STTR records share this UEI (2008–2009). Reported award amounts total $1,236,189. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.